{"hands_on_practices": [{"introduction": "A fundamental challenge in diagnostic serology is ensuring that results are comparable across different laboratories, reagent lots, and time. This exercise [@problem_id:4691004] demonstrates the crucial process of standardizing a quantitative immunoassay by converting raw instrumental signals into universally recognized units, such as the World Health Organization's Binding Antibody Units per milliliter (BAU/mL). By applying a simple linear calibration, you will practice a foundational skill that underpins the reliability and interoperability of modern serologic testing.", "problem": "A clinical laboratory uses an enzyme-linked immunosorbent assay (ELISA) to quantify pathogen-specific immunoglobulin G (IgG) antibodies. The assay reports a dimensionless raw signal, called an index, that is proportional to the concentration of binding antibodies under validated operating conditions. The laboratory has aligned its assay to the World Health Organization (WHO) International Standard for antibodies, which defines Binding Antibody Units per milliliter (BAU/mL) as the standardized concentration unit. Calibration against the WHO International Standard yielded a lot-specific linear mapping from index to BAU/mL with slope $k$ and a statistically negligible intercept across the validated analytical measuring interval. For the current reagent lot, the slope is $k = 0.142$ BAU/mL per index.\n\nThree patient samples produced raw index values $I_{1} = 12$, $I_{2} = 35$, and $I_{3} = 80$, all within the assayâ€™s validated linear range. Using foundational principles that relate immunoassay signal to analyte concentration and the provided calibration characterization, convert these index values to concentrations in the WHO-standardized unit. Report each concentration in Binding Antibody Units per milliliter (BAU/mL) and round each result to three significant figures.", "solution": "The problem is deemed valid as it is scientifically grounded, well-posed, and objective. It presents a standard calibration problem in analytical chemistry and clinical diagnostics, free of contradictions or ambiguities.\n\nThe problem states that the concentration of binding antibodies, $C$, measured in Binding Antibody Units per milliliter (BAU/mL), is related to a dimensionless raw signal, the index $I$, by a lot-specific linear mapping. The general form of a linear relationship is:\n$$\nC(I) = mI + b\n$$\nwhere $m$ is the slope and $b$ is the y-intercept.\n\nAccording to the problem statement, this linear mapping has a slope $k$ and a \"statistically negligible intercept.\" This is a formal instruction to model the relationship with an intercept of zero. Therefore, we set $m = k$ and $b = 0$. The governing equation simplifies to a direct proportionality:\n$$\nC = kI\n$$\nThe value of the slope for the current reagent lot is provided as:\n$$\nk = 0.142 \\text{ BAU/mL per index}\n$$\nThe problem requires the conversion of three raw index values, $I_{1} = 12$, $I_{2} = 35$, and $I_{3} = 80$, into their corresponding concentrations in BAU/mL. All given index values are within the validated linear range of the assay, confirming the applicability of the derived equation.\n\nFor the first patient sample with index $I_1 = 12$:\n$$\nC_1 = k \\times I_1 = 0.142 \\times 12 = 1.704\n$$\nRounding this result to three significant figures gives $1.70$.\n\nFor the second patient sample with index $I_2 = 35$:\n$$\nC_2 = k \\times I_2 = 0.142 \\times 35 = 4.97\n$$\nThis result is already expressed with three significant figures.\n\nFor the third patient sample with index $I_3 = 80$:\n$$\nC_3 = k \\times I_3 = 0.142 \\times 80 = 11.36\n$$\nRounding this result to three significant figures gives $11.4$.\n\nThus, the concentrations corresponding to the index values $12$, $35$, and $80$ are $1.70$ BAU/mL, $4.97$ BAU/mL, and $11.4$ BAU/mL, respectively.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n1.70 & 4.97 & 11.4\n\\end{pmatrix}\n}\n$$", "id": "4691004"}, {"introduction": "While sensitivity and specificity describe the intrinsic accuracy of a serologic test, its practical utility in a clinical or public health setting depends heavily on the prevalence of the disease in the population being tested. This exercise [@problem_id:4691012] challenges you to apply Bayes' theorem to calculate a test's positive and negative predictive values ($PPV$ and $NPV$). By working through this classic scenario, you will gain a crucial understanding of how pre-test probability can dramatically alter the reliability of a positive result, a foundational concept for designing and interpreting screening programs.", "problem": "An academic public health team is evaluating a serologic screening program for an emerging viral infection using an Enzyme-Linked Immunosorbent Assay (ELISA). Assume a closed population in which the infection status at the time of testing is static, and let the pre-test probability of infection equal the population prevalence. The assay has sensitivity $Se$ and specificity $Sp$. By definition, sensitivity is the probability of a positive result given true infection, and specificity is the probability of a negative result given true non-infection. Positive predictive value (PPV) is the probability of true infection given a positive test result, and negative predictive value (NPV) is the probability of true non-infection given a negative test result.\n\nGiven $Se = 0.95$, $Sp = 0.98$, and a prevalence of infection $0.02$, use the foundational probability definitions and rules (including the law of total probability) to derive expressions for PPV and NPV from first principles and then compute their numerical values. Based on the computed values, briefly interpret the implications for population screening with this ELISA, including how the pre-test probability influences the reliability of positive versus negative results.\n\nExpress PPV and NPV as dimensionless decimals, each rounded to four significant figures. Do not use a percentage sign.", "solution": "The problem is well-posed and provides all necessary information to derive and compute the positive predictive value ($PPV$) and negative predictive value ($NPV$) of a serologic assay.\n\nLet us define the events:\n- $D$: The event that an individual is truly infected with the virus.\n- $D^c$: The event that an individual is not infected.\n- $T^+$: The event that the test result is positive.\n- $T^-$: The event that the test result is negative.\n\nThe givens can be translated into probabilistic terms. Let $P(D)$ be the prevalence of the infection, which is also the pre-test probability.\n- Prevalence: $P(D) = 0.02$.\n- The probability of not being infected is $P(D^c) = 1 - P(D) = 1 - 0.02 = 0.98$.\n- Sensitivity ($Se$): The probability of a positive test given infection, $Se = P(T^+ | D) = 0.95$.\n- Specificity ($Sp$): The probability of a negative test given non-infection, $Sp = P(T^- | D^c) = 0.98$.\n\nFrom these definitions, we can derive the probabilities of the complementary events:\n- The probability of a false negative is $P(T^- | D) = 1 - P(T^+ | D) = 1 - Se = 1 - 0.95 = 0.05$.\n- The probability of a false positive is $P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - Sp = 1 - 0.98 = 0.02$.\n\nThe task is to derive expressions for $PPV$ and $NPV$ from first principles and compute their values.\n\n**Derivation and Calculation of Positive Predictive Value (PPV)**\n\nThe $PPV$ is the probability of being infected given a positive test result, which is the conditional probability $P(D | T^+)$. We use Bayes' theorem to find this value:\n$$PPV = P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)}$$\nThe denominator, $P(T^+)$, is the total probability of obtaining a positive test result. It can be found by applying the law of total probability, summing over the two possible states of infection:\n$$P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)$$\nThis expression represents the sum of the probabilities of true positives and false positives. Substituting the symbols for sensitivity, specificity, and prevalence:\n$$P(T^+) = (Se \\cdot P(D)) + ((1 - Sp) \\cdot P(D^c))$$\n$$P(T^+) = (Se \\cdot P(D)) + ((1 - Sp) \\cdot (1 - P(D)))$$\nNow, we substitute this back into the formula for $PPV$:\n$$PPV = \\frac{Se \\cdot P(D)}{Se \\cdot P(D) + (1 - Sp) \\cdot (1 - P(D))}$$\nThis is the derived expression for $PPV$ from first principles.\n\nNow, we compute the numerical value using the given data: $Se = 0.95$, $Sp = 0.98$, and $P(D) = 0.02$.\n$$PPV = \\frac{0.95 \\cdot 0.02}{0.95 \\cdot 0.02 + (1 - 0.98) \\cdot (1 - 0.02)}$$\n$$PPV = \\frac{0.019}{0.019 + (0.02 \\cdot 0.98)}$$\n$$PPV = \\frac{0.019}{0.019 + 0.0196}$$\n$$PPV = \\frac{0.019}{0.0386} \\approx 0.492227979...$$\nRounding to four significant figures, we get $PPV = 0.4922$.\n\n**Derivation and Calculation of Negative Predictive Value (NPV)**\n\nThe $NPV$ is the probability of not being infected given a negative test result, which is the conditional probability $P(D^c | T^-)$. Again, we use Bayes' theorem:\n$$NPV = P(D^c | T^-) = \\frac{P(T^- | D^c) P(D^c)}{P(T^-)}$$\nThe denominator, $P(T^-)$, is the total probability of obtaining a negative test result. Using the law of total probability:\n$$P(T^-) = P(T^- | D^c) P(D^c) + P(T^- | D) P(D)$$\nThis represents the sum of the probabilities of true negatives and false negatives. Substituting the symbols:\n$$P(T^-) = (Sp \\cdot P(D^c)) + ((1 - Se) \\cdot P(D))$$\n$$P(T^-) = (Sp \\cdot (1 - P(D))) + ((1 - Se) \\cdot P(D))$$\nSubstituting this back into the formula for $NPV$:\n$$NPV = \\frac{Sp \\cdot (1 - P(D))}{Sp \\cdot (1 - P(D)) + (1 - Se) \\cdot P(D)}$$\nThis is the derived expression for $NPV$ from first principles.\n\nNow, we compute the numerical value:\n$$NPV = \\frac{0.98 \\cdot (1 - 0.02)}{0.98 \\cdot (1 - 0.02) + (1 - 0.95) \\cdot 0.02}$$\n$$NPV = \\frac{0.98 \\cdot 0.98}{0.98 \\cdot 0.98 + 0.05 \\cdot 0.02}$$\n$$NPV = \\frac{0.9604}{0.9604 + 0.001}$$\n$$NPV = \\frac{0.9604}{0.9614} \\approx 0.998959850...$$\nRounding to four significant figures, we get $NPV = 0.9990$.\n\n**Interpretation of Results**\n\nThe computed $PPV$ is $0.4922$ and the $NPV$ is $0.9990$.\nThe very high $NPV$ ($99.90\\%$) implies that a negative test result is extremely reliable. If a person tests negative, it is almost certain that they do not have the infection. This makes the test very effective for ruling out the disease.\n\nIn stark contrast, the $PPV$ is low at $0.4922$ ($49.22\\%$). This signifies that a positive test result is highly unreliable for confirming the infection. For an individual who tests positive, the probability of them actually being infected is less than $50\\%$. The chance of a false positive is slightly greater than the chance of a true positive.\n\nThis discrepancy is a classic illustration of the effect of prevalence (the pre-test probability) on predictive values. Even with a high specificity of $98\\%$, the low prevalence of $2\\%$ means that the absolute number of healthy individuals is very large compared to the number of infected individuals. Consequently, the small fraction of false positives from the large healthy population ($98,000$ out of $100,000$, yielding $1,960$ false positives) becomes comparable in number to the true positives from the small infected population ($2,000$ out of $100,000$, yielding $1,900$ true positives). This makes a positive result ambiguous.\n\nThe implication for population screening is that this ELISA is an excellent tool for ruling out the infection but is a poor tool for confirmation in a low-prevalence setting. A positive screening result should not be considered definitive and must be followed up with a more specific, confirmatory test to minimize misdiagnosis and unnecessary anxiety or treatment. The reliability of a positive result heavily depends on the pre-test probability, whereas the reliability of a negative result is less affected under these conditions.", "answer": "$$\\boxed{\\begin{pmatrix} 0.4922 & 0.9990 \\end{pmatrix}}$$", "id": "4691012"}, {"introduction": "Real-world diagnostic decisions rarely hinge on a single test; instead, they rely on carefully constructed testing algorithms that combine multiple assays to maximize accuracy and efficiency. This final practice problem [@problem_id:4690983] builds directly upon the principles of predictive value to evaluate and compare two competing screening workflows for syphilis. By calculating the expected fraction of false-positive referrals in different prevalence settings, you will learn how to quantitatively assess the public health implications of algorithm design, a critical skill for laboratory directors and epidemiologists.", "problem": "A public health laboratory is evaluating two screening workflows for syphilis serologic testing. In the traditional workflow, individuals are first screened with a nontreponemal test such as the Rapid Plasma Reagin (RPR) or Venereal Disease Research Laboratory (VDRL). In the reverse workflow, individuals are first screened with a treponemal test such as an enzyme immunoassay. For a screening test with sensitivity $Se$ and specificity $Sp$, let the population prevalence of true infection be $p$. In both workflows, an individual with a reactive initial screen is referred for confirmatory testing.\n\nUsing the fundamental definitions that sensitivity is the probability that a test is reactive given true infection, specificity is the probability that a test is nonreactive given no infection, and prevalence is the probability of true infection in the population, derive from first principles the expected fraction of referred individuals (reactive on the initial screen) who are uninfected, as a function of $p$, $Se$, and $Sp$. Then, using the following scientifically plausible parameters for the initial screening tests: treponemal test sensitivity $Se_{trep}=0.98$, treponemal test specificity $Sp_{trep}=0.96$, nontreponemal test sensitivity $Se_{nontrep}=0.86$, and nontreponemal test specificity $Sp_{nontrep}=0.98$, compute this expected fraction for both workflows at two population prevalences $p=0.005$ and $p=0.05$.\n\nReport the four numerical results in the order $(\\text{traditional at } p=0.005,\\ \\text{reverse at } p=0.005,\\ \\text{traditional at } p=0.05,\\ \\text{reverse at } p=0.05)$ as decimal fractions, and round your answers to four significant figures.", "solution": "The problem is well-posed, providing a clear scenario to apply the principles of diagnostic test evaluation. It asks for the derivation and calculation of the expected fraction of referred individuals (those with a reactive screen) who are actually uninfected. This quantity is the conditional probability $P(\\text{Uninfected} | \\text{Reactive Screen})$, which is also known as the False Discovery Rate and is equal to $1 - \\text{Positive Predictive Value (PPV)}$.\n\nLet's define the events:\n- $D$: The event that an individual has a true infection.\n- $D^c$: The event that an individual is uninfected.\n- $T^+$: The event that the screening test is reactive (positive).\n\nThe given parameters in the problem's notation are:\n- Prevalence: $p = P(D)$\n- Sensitivity: $Se = P(T^+ | D)$\n- Specificity: $Sp = P(T^- | D^c)$, where $T^-$ is a nonreactive test.\n\nFrom these, we can derive:\n- $P(D^c) = 1 - p$\n- Probability of a false positive: $P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - Sp$\n\nThe quantity to derive is the fraction of referred individuals who are uninfected, which is $P(D^c | T^+)$. Using Bayes' theorem:\n$$\nP(D^c | T^+) = \\frac{P(T^+ | D^c) P(D^c)}{P(T^+)}\n$$\nThe denominator, $P(T^+)$, is the total probability of a reactive screen, found using the law of total probability:\n$$\nP(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)\n$$\nSubstituting the problem's notation into these equations:\n$$\nP(T^+) = (Se \\cdot p) + ((1 - Sp) \\cdot (1 - p))\n$$\nAnd therefore, the desired fraction is:\n$$\n\\text{Fraction of uninfected among referred} = P(D^c | T^+) = \\frac{(1 - Sp)(1 - p)}{Se \\cdot p + (1 - Sp)(1 - p)}\n$$\nThis is the general formula derived from first principles. We will now apply it to the two workflows at the two specified prevalences.\n\n**1. Traditional Workflow (Nontreponemal Screen)**\nParameters: $Se_{nontrep} = 0.86$, $Sp_{nontrep} = 0.98$.\n- **At prevalence $p = 0.005$:**\n  $$\n  \\text{Fraction} = \\frac{(1 - 0.98)(1 - 0.005)}{0.86 \\cdot 0.005 + (1 - 0.98)(1 - 0.005)} = \\frac{0.02 \\cdot 0.995}{0.0043 + 0.0199} = \\frac{0.0199}{0.0242} \\approx 0.822314...\n  $$\n  Rounded to four significant figures: **0.8223**.\n\n- **At prevalence $p = 0.05$:**\n  $$\n  \\text{Fraction} = \\frac{(1 - 0.98)(1 - 0.05)}{0.86 \\cdot 0.05 + (1 - 0.98)(1 - 0.05)} = \\frac{0.02 \\cdot 0.95}{0.043 + 0.019} = \\frac{0.019}{0.062} \\approx 0.30645...\n  $$\n  Rounded to four significant figures: **0.3065**.\n\n**2. Reverse Workflow (Treponemal Screen)**\nParameters: $Se_{trep} = 0.98$, $Sp_{trep} = 0.96$.\n- **At prevalence $p = 0.005$:**\n  $$\n  \\text{Fraction} = \\frac{(1 - 0.96)(1 - 0.005)}{0.98 \\cdot 0.005 + (1 - 0.96)(1 - 0.005)} = \\frac{0.04 \\cdot 0.995}{0.0049 + 0.0398} = \\frac{0.0398}{0.0447} \\approx 0.89038...\n  $$\n  Rounded to four significant figures: **0.8904**.\n\n- **At prevalence $p = 0.05$:**\n  $$\n  \\text{Fraction} = \\frac{(1 - 0.96)(1 - 0.05)}{0.98 \\cdot 0.05 + (1 - 0.96)(1 - 0.05)} = \\frac{0.04 \\cdot 0.95}{0.049 + 0.038} = \\frac{0.038}{0.087} \\approx 0.43678...\n  $$\n  Rounded to four significant figures: **0.4368**.\n\nThe four numerical results in the requested order are (0.8223, 0.8904, 0.3065, 0.4368). These results highlight that in a low-prevalence setting ($p=0.005$), both workflows generate a high fraction of false-positive referrals (82% and 89%), with the lower specificity of the reverse screen leading to a worse outcome in this specific metric. In a higher-prevalence setting ($p=0.05$), the fraction of false positives drops significantly for both workflows, though the reverse workflow still refers a higher proportion of uninfected individuals due to its lower specificity.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.8223 & 0.8904 & 0.3065 & 0.4368\n\\end{pmatrix}\n}\n$$", "id": "4690983"}]}